• Skip to main content
  • Skip to footer
cnb1383_liver-model-drug-safety_webinar_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals

March 19, 2015

CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc.

Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN Bio’s facility in Welwyn Garden City, UK and take advantage CN Bio’s proprietary LiverChip® 3D perfused culture platform. This research seeks to determine the feasibility of using CN Bio’s high integrity models for rapid and accurate in vitro testing of Isis’ anti-viral drug candidates.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis’ broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases. Isis’ patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

About CN Bio Innovations

CN Bio Innovations is part of Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases, including Hepatitis B and C. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. Additional information about CN Bio is available at www.cn-bio.com.

Category iconBusiness

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025
Cyber Essentials Logo